20 articles
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Scientists discover how small cell lung cancer uses inflammation to become more aggressive and resistant to treatment.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Key biotech companies developing T cell engager therapies that redirect immune cells to fight cancer more effectively.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
New biotech innovations are advancing prostate cancer therapy with promising approaches for better patient outcomes.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
New research reveals how tumors reprogram neutrophils to produce CCL3, turning immune defenders into cancer allies.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within — and blocking it may revive failed immunotherapies.
A protein called HOXD13 drives skin cancer growth and shields tumors from immune cells — disabling it could unlock powerful new treatments.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Plant compounds naturally target multiple cancer pathways simultaneously, offering advantages over pharmaceutical approaches.
Revolutionary CRISPR technique bypasses lab manufacturing by programming immune cells to fight cancer directly in the body.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
A new imaging breakthrough reveals how immune cells target cancer with nanoscale precision, opening doors for better immunotherapy.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
